Wenn Sie mit der Nutzung dieser Website fortfahren, stimmen Sie dem Einsatz von Cookies auf Ihrem Gerät zu. Lesen Sie hier mehr über unsere Cookie Policy und welche Arten von Cookies wir verwenden.

Update: UBS ETF (CH) – SMI

Der Schweizer Standardwerte-Index SMI wird von den drei Konzernen Novartis, Nestlé und Roche dominiert. Etwas breiter diversifiziert sind der SLI und SPI, wobei auch hier die Pharma- und Konsumgüterbranchen sehr prominent vertreten sind.

Hortense Bioy, CFA 09.10.2015

Rolle im Portfolio

The UBS ETF (CH) SMI provides exposure to Swiss large cap stocks, some of which are also the biggest in Europe. As such, this fund can be used as a core holding, but investors should be aware of the peculiarities of the underlying index. The SMI is extremely top heavy, with the top three constituents, namely Nestle, Novartis and Roche, accounting for about 60% of the index’s value. This inevitably results in high sector concentration, with healthcare accounting for 39-42% of the index's value, while consumer goods and financials combined represent another 43-45%.

This fund can also be implemented as a tactical tool to overweight Swiss large cap equities within a diversified portfolio.

Additionally, for non-Swiss investors, this fund can serve as a diversifier within a broad pan-European portfolio by providing exposure to the Swiss franc, arguably one of the world’s most stable and strongest currencies. However those investors should be mindful that while a strengthening franc will enhance the return of this fund as denominated in their home currencies, a weakening franc will weigh on its performance as measured in their home currency.

Go to top

Fundamentale Analyse

The SMI consists of many high-quality companies that boast sustainable competitive advantages, or wide “economic moats”, by virtue of having either exclusive patents or well-recognised brand names. These include not only multinationals like Nestle, Richemont or Swatch, but also defensive heavyweights like Novartis and Roche which are able to maintain a competitive advantage with their portfolio of patented drugs and robust R&D budgets, which support new drug discovery.

Thanks to their high value-added nature, these companies weathered the global financial and economic crisis better than many others. They also showed resilience to the strong franc, which, driven by its safe-haven status, appreciated considerably after the crisis.

However, threatening to thwart growth and sink the country into sustained deflation, the persistent strength of the franc prompted the Swiss National Bank (SNB) to set the minimum exchange rate to the euro at 1.20 in September 2011. The cap was subsequently dropped in January 2015 in anticipation of the European Central Bank (ECB)’s quantitative easing (QE) programme, which would have made the cap too costly to sustain. At the same time, the SNB cut interest rates to -0.75% in an attempt to discourage currency appreciation. Swiss equities tumbled on the news but they have since recovered. The Swiss franc, nevertheless, is still too strong and continues to weigh on exporters, especially those that generate most of their sales outside Switzerland but manufacture domestically.

Another source of concerns for Swiss companies is the slowdown in emerging markets, and particularly China. Swiss companies have increased their exports to China and are now more dependent than ever on its economic growth. The world’s No 2 economy continues to post robust growth rates of 5.5-6%, but this is lower than what the world had become accustomed to.

By contrast, macroeconomic conditions are improving in Europe helped by the ECB’s QE programme, lower energy prices and a weaker euro.

Go to top

Indexkonstruktion

The Swiss Market Index (SMI) is the benchmark index of the Swiss stock market. It is a free-float-adjusted index that comprises 20 of the largest and most liquid stocks listed on the Swiss stock exchange. The SMI represents about 85% of the total capitalisation of the Swiss equity market and its composition is examined once a year. The healthcare sector is the most heavily weighted, representing 39-42% of the index's value, followed by consumer goods (26-30%), financials (16-20%) and industrials (7-10%). The index is extremely top heavy, with Novartis and Nestle accounting for 21-25% of the index’s value each. The third largest stock represented is Roche, with a 16-20% weight.

Go to top

Fondskonstruktion

The fund uses full physical replication to track the performance of the SMI total return index. The fund holds all the securities within the index. Dividends received from the underlying stocks are invested in the index until distribution date. This dividend treatment helps to minimise tracking error. The ETF engages in securities lending to help improve its tracking performance. The amount of securities that can be lent by an ETF at any point in time is capped at 50% of its net asset value (NAV). Lending operations are protected by taking high-quality collateral (e.g. G10 government bonds and equities listed on globally-recognised indices) greater than the loan value. The level of overcollateralisation is set at 105% for bonds and stocks. Cash is not accepted as collateral. Both loan and collateral values are marked-to-marked daily. State Street Bank, who acts as the lending agent, provides full indemnification to the ETF in case of a borrower failure to return the securities. Gross lending revenue is split as follows: 60% to the ETF, 40% to UBS/State Street Bank, with the latter covering all associated operational costs. The net return to the fund was 0.004% for the last 12 months, while 3.9% of the fund’s NAV was lent out on average and a maximum percentage of the total NAV lent on any single day of 24.2%. It is worth noting that this Swiss-domiciled ETF is not compliant with UCITS III and therefore is only authorised for commercial distribution in Switzerland and Liechtenstein.

Go to top

Gebühren

At 0.20%, the fund charges the lowest total expense ratio (TER) of all the ETFs tracking the SMI. The tracking difference (fund return - index return) over the last three years suggests that the fund's total holding cost per annum is higher. On top of holding costs, ETF investors will typically be charged trading costs, including bid-offer spreads and brokerage commissions, when buy and sell orders are placed for ETF shares.

Go to top

Alternativen

iShares and db X-trackers offer alternative SMI ETFs, albeit at higher TERs.

As an alternative to SMI ETFs, there is the Amundi MSCI Switzerland ETF, with a TER of 0.25%, and the UBS MSCI Switzerland ETF, which charges a TER of 0.20%. Consisting of 36 stocks, the MSCI Switzerland is larger than the SMI but still very top heavy, with the top 10 names accounting for about 90% of the index and very marginal exposure to the Swiss midcap market.

Those concerned about the high concentration risk embedded in SMI and MSCI Switzerland ETFs could look at ETFs tracking the SLI. The SLI index consists of the 30 largest and most liquid stocks on the Swiss equity market and has a capping mechanism. The index weighting of the four largest constituents is limited to 9% and the weighting of all other stocks to 4.5%. As a result, this fund has higher weightings in industrials and basic materials. UBS and db x-trackers provide the cheapest options tracking the SLI (strictly in terms of TER), each sporting a TER of 0.35%.

Finally, those looking for broader market exposure could consider ETFs tracking the SPI, which is composed of large, mid and small caps. The iShares Core SPI (CH) charges a TER of 0.10%.

Go to top

Über den Autor Hortense Bioy, CFA

Hortense Bioy, CFA  is director of passive fund research in Europe.